We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $581M
1-Year Est. Return 373.68%
This Fund
S&P 500
This Quarter Est. Return
+54.5%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$583M
AUM Growth
+$84.1M
Cap. Flow
-$28.8M
Cap. Flow %
-4.93%
Top 10 Hldgs %
45.64%
Holding
119
New
32
Increased
28
Reduced
17
Closed
42

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$25.6M
2
ABVX
Abivax
ABVX
+$24.6M
3
TWST icon
Twist Bioscience
TWST
+$16.2M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$12.6M
5
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.9M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$63.7M
2
DNLI icon
Denali Therapeutics
DNLI
+$22.2M
3
IMVT icon
Immunovant
IMVT
+$21.1M
4
QURE icon
uniQure
QURE
+$18.5M
5
WVE icon
Wave Life Sciences
WVE
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
2 Miscellaneous 0.09%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTGN icon
76
VistaGen Therapeutics
VTGN
$10.8M
$142K 0.02%
616,749
-1,871,936
-75% -$6.76M
CNTA
77
CALL
DELISTED
Centessa Pharmaceuticals
CNTA
$26.3K ﹤0.01%
75,000
-97,500
-57% -$2.47M
ABUS icon
78
CALL
Arbutus Biopharma
ABUS
$1.02B
– –
-95,000
Closed -$9.5K
AKRO
79
DELISTED
Akero Therapeutics
AKRO
– –
-121,410
Closed -$5.76M
AKRO
80
PUT
DELISTED
Akero Therapeutics
AKRO
– –
-15,500
Closed -$9.69K
ALKS icon
81
Alkermes
ALKS
$7.73B
– –
-241,637
Closed -$7.25M
ARCT icon
82
Arcturus Therapeutics
ARCT
$450M
– –
-35,606
Closed -$656K
ARGX icon
83
argenx
ARGX
$64.6B
– –
-12,465
Closed -$9.19M
ARKG icon
84
CALL
ARK Genomic Revolution ETF
ARKG
$2B
– –
-200,000
Closed -$30K
ATAI icon
85
AtaiBeckley Inc
ATAI
$2.74B
– –
-76,032
Closed -$402K
BBIO icon
86
BridgeBio Pharma
BBIO
$14.6B
– –
-127,435
Closed -$6.62M
BHVN icon
87
CALL
Biohaven
BHVN
$2.37B
– –
-480,000
Closed -$1.19M
BHVN icon
88
Biohaven
BHVN
$2.37B
– –
-1,017,311
Closed -$15.3M
CDTX
89
DELISTED
Cidara Therapeutics
CDTX
– –
-152,325
Closed -$14.6M
CGON icon
90
CG Oncology
CGON
$6.62B
– –
-63,019
Closed -$2.54M
CMPS
91
Compass Pathways
CMPS
$1.84B
– –
-275,620
Closed -$1.58M
CRSP icon
92
CALL
CRISPR Therapeutics
CRSP
$5.39B
– –
-40,000
Closed -$59K
CRVS icon
93
Corvus Pharmaceuticals
CRVS
$1.21B
– –
-96,439
Closed -$711K
ENTA icon
94
Enanta Pharmaceuticals
ENTA
$410M
– –
-75,194
Closed -$900K
EQ icon
95
Equillium
EQ
$140M
– –
-1,908,935
Closed -$2.73M
GHRS icon
96
GH Research
GHRS
$1.94B
– –
-545,275
Closed -$7.8M
HROW icon
97
Harrow
HROW
$1.44B
– –
-57,619
Closed -$2.78M
IMVT icon
98
CALL
Immunovant
IMVT
$8.11B
– –
-250,000
Closed -$50K
INSM icon
99
Insmed
INSM
$27.6B
– –
-43,419
Closed -$6.25M
IONS icon
100
CALL
Ionis Pharmaceuticals
IONS
$9.65B
– –
-50,000
Closed -$138K
1 2 3
4
5

Similar funds

PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
Cambridge Advisors Omaha, Nebraska $582M AUM 19.14% 1-Year Est. Return

Stempoint Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Stempoint Capital held 119 positions worth $583M, up 17% from $499M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Stempoint Capital withdrew a net $28.8M in Q4 2025, closing 42 positions and reducing 17 holdings. Its most notable exit was Wave Life Sciences, an estimated $15.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Stempoint Capital opened a new position in Twist Bioscience worth $16.4M.

  • Stempoint Capital's largest Q4 2025 buy was Twist Bioscience: 518,355 shares worth $16.4M.
  • Stempoint Capital added most to Arcellx in Q4 2025, an estimated $25.6M increase.
  • Stempoint Capital's biggest Q4 2025 reduction was Roivant Sciences, cutting an estimated $63.7M.
  • Stempoint Capital fully exited Wave Life Sciences in Q4 2025, selling an estimated $15.4M.
  • Stempoint Capital's ten largest holdings make up 46% of its $583M portfolio in Q4 2025.
  • Stempoint Capital opened 32 new positions and closed 42 in Q4 2025.
  • Stempoint Capital's portfolio value rose 17% quarter-over-quarter to $583M.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.